Press Releases

3 July 2024 - Paras Biopharmaceuticals Announces Successful Client Audit as Critical Supplier for Recombinant Biologics (Bulk) – Ancillary Materials
27 June 2024 - Paras Biopharmaceuticals’ Innovative Biologics Production Capabilities and Unique Technologies Showcased at BIO USA 2024
27 June 2024 - Full Transcript of Dr. Ashesh Kumar – Paras Biopharmaceuticals Interview with Global Message at BIO USA 2024
4 July 2023 - Paras Biopharma (Biologics CDMO) Maximises Recombinant Protein Expression in Microbial Systems – To Facilitate Economical Scale-up in Production of Biologics
18 May 2023 - Inc. Magazine, USA includes Paras Biopharma (Biologics CDMO) as one of the Top 10 Most Innovative Biotech Companies to Follow in 2023
19 December 2022 - Paras Biopharmaceuticals Creates Excellence with “Continuous Biomanufacturing”: Achieves objectives of “High Productivity & Biomanufacturing Innovation”
12 December 2022 - Paras Biopharma Streamlines Offerings as “Biologics CDMO” and Biosimilar Co-Development as “Paras Biologics”
29 November 2022 - Paras Biopharmaceuticals Finland Oy is Highly Recommended for Biologics CDMO – Development / Scale-up & Production of Biologics by Innovative USA Biopharma Company
1 September 2022 - Paras Biopharmaceuticals Finland Oy – has been identified as one of the “Fastest Growing Companies in the Nordic Biotechnology Therapeutics & Diagnostics Industry” by Plimsoll Publishing Ltd. UK
3 May 2022 - Paras Biopharmaceuticals Finland Oy – Exploring Reverse Merger Opportunity
29 March 2022 - Expansion of Biologics CDMO & Manufacturing Capacity Offerings at Paras Biopharmaceuticals Finland Oy
2nd March 2022 – Paras Biopharmaceuticals is now a member of Bioseet Platform, to expand global outreach of its ‘Biosimilar Development & Partnership
22nd February 2022 - Paras Biopharmaceuticals is one of the SUPERFINNS®
22nd June 2021 - Paras Biopharmaceuticals Finland Oy named as one of the Top Pharma Outsourcing Companies in Europe 2021
28th April 2021 - Paras Biopharma on the list of 30 Admired Companies to Watch by CIO Bulletin, USA
16th February 2021 - Paras Biopharmaceuticals Finland Oy Affordable Healthcare Efforts Viewed in over 90 Countries: Biosimilar Technologies get Attention.
8th September, 2020 Paras Biopharmaceuticals – Now a Member of PSL Alliance
10th September 2019 Paras Biopharmaceuticals - Successful Development of Cytofold StructQuant® Technology
7th May 2019: Reuters to make a documentary on Paras Biopharmaceuticals Finland Oy – Innovations in Biologics: Insights of a leading expert.
1st February, 2019: Paras Biopharmaceuticals Finland Oy Announces Successful Development of Biologically Active Romiplostim (N-Plate® Biosimilar) Production Technology
9th October, 2018: Affordable Healthcare in Oulu Closer than Ever: Paras Biopharmaceuticals Finland Oy Significantly Invests in Oulu Biologics Production Site
12th December 2016: Paras Biopharmaceuticals receives Quality Choice award from European Society for Quality Research, Switzerland
25th August 2016: Oulu-based Paras Biopharmaceuticals develops technology for Osteoporosis biosimilar drug & brings international investments. Expansion scheduled in Oulu.
24th November 2015: Paras Biopharmaceuticals forms partnership with Novozymes to embrace Veltis® technology for once-a-week Teriparatide Biobetter for Osteoporosis
28th April 2015: Paras Biopharmaceuticals Finland Oy Selected as First Finnish Company to Present at Cavendish Global Health Impact Forum
11th December 2014: Paras Biopharmaceuticals wins the 2014 European Biopharmaceuticals Technology Innovation Leadership Award by Frost & Sullivan

News Events

Paras Biopharmaceuticals acquires new Aglient Q-TOF to expand analytical capabilities

12th January 2016: Paras Biopharmaceuticals has announced the expansion of its analytical capabilities with the procurement of a Agilent 6530 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF) and UHPLC systems for peptide identification. This devices provides exceptional MS and MS/MS performance without compromises and will allow Paras to add to its existing analytical suite.

Paras Biopharmaceuticals receives Quality Choice award from European Society for Quality Research, Switzerland

Based on their products and its continuous drive to push the limits of Quality with innovations, Paras Biopharmaceuticals has received the ESQR's Quality Choice Prize 2016 for their hard work and achievements, in the presence of the international business community for its commitment to quality, excellence and continuous improvement. 12th December 2016 in Berlin, Germany

Biochemistry Students participate in fact-finding tour of our facility

As part of Paras Biopharmaceuticals' corporate social responsibility initiative to encourage students into the fields of biochemistry and biopharmaceutical production, on 18th November 2016 Paras Biopharmaceuticals welcomed Histoni Ry and its members to its Oulu-based facility. Histoni Ry is the student organisation of the biochemistry department at the University of Oulu.

Paras Biopharmaceuticals upgrades its purification suite to expand existing capabilities.

19th September 2016. Paras Biopharmaceuticals expands its purification suite with the addition of low-pressure AxiChrom columns from GE Healthcare Life Sciences. The most notable addition is the AxiChrom 300 column and AxiChrom Packing Master.

Oulu-based Paras Biopharmaceuticals develops technology for Osteoporosis biosimilar drug & brings international investments. Expansion scheduled in Oulu.

25th August 2016, - Oulu-based Paras Biopharmaceuticals Finland Oy has developed technology for the production of an osteoporosis drug (Recombinant Teriparatide) which will result into a very economical production of the medicine. International pharma companies are actively in discussions with Paras Biopharmaceuticals to further take regulatory work and bring the medicine to market.

Paras forms partnership with Novozymes (Denmark)

In collaboration with Novozymes (Denmark), Paras Biopharmaceuticals (Finland) announced that the partnership will use the successful VELTIS® technology to develop an improved version of a leading osteoporosis treatment. 24th November 2015

Paras' corporate social responsibility initiative

Biotechnology students from the University of Oulu take up the chance to explore Paras' facilities. 12th November 2015

Paras wins international award

On 11th December 2014 in Frankfurt, Germany, senior members of the Paras Team received an international award by the US company Frost & Sullivan.

Paras in the news: "Oulu doesn't give up"

Reported on 7th Aug 2014 by Helsinki-based business newspaper "Kauppalehti"

Paras' corporate social responsibility initiative

8th grade students from Oulu International School take up the chance to explore Paras' facilities. 22th April 2014

Paras' corporate social responsibility initiative

Biotechnology students from Tampere University of Technology take up the chance to explore Paras' facilities. 28th March 2014

Paras in the news: "Medicine cost down using Oulu-based knowledge"

Reported by Oulu's local newspaper "Kaleva" (13th October 2013)

Media Contact

Dr. Mark Jackson
Public Affairs
mark.jackson@parasbiopharma.com